Questions of discovery and efficacy are pivotal in patenting new products, as Editha Hechanova and Fe Belen Bello explain.
On February 15, 2012, the Intellectual Property Offce of the Philippines (IPPHL) published on its website its Examination Guidelines for Pharmaceutical Patent Applications Involving Known Substances.
These guidelines were issued pursuant to the amendments in the patent law and its implementing rules and regulations, brought about by Republic Act No. 9502, the Universally Accessible Cheaper and Quality Medicines Act of 2008 (QUAMA).
The aim of this act is to promote and ensure access to affordable quality drugs and medicines for all, pursuant to the state’s policy of protecting public health.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.
efficacy, pharmaceuticals, QUAMA, patent applications